Horizon Pharma (HZNP) Tops Q3 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. DDOG
8. CPAY
9. MCD
10. CHYM

Go back to Horizon Pharma (HZNP) Tops Q3 EPS by 15c

Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance

November 7, 2018 7:00 AM EST

-- Quarterly Net Sales Increased 20 Percent to $325.3 Million, a Record for the Company; Third-Quarter 2018 GAAP Net Income of $26.0 Million; Adjusted EBITDA of $149.9 Million --

-- Quarterly Orphan and Rheumatology Segment Net Sales Increased 25 Percent to $219.9 Million; Represented 68 Percent of Total Company Net Sales --

-- Third-Quarter 2018 KRYSTEXXA® Net Sales Growth of 64 Percent; Continue to Expect Full-Year 2018 Net Sales Growth of More Than 65 Percent --

-- Adapting KRYSTEXXA MIRROR Clinical Trial to Support Potential for Registration; Decision Follows Encouraging External Case Series Showing Markedly Improved... More